E. Manolescu *, Smaranda Petrescu *, L. Stoleru **
* Prof. Dr. Emanoil Manolescu, Dr. Smaranda Petrescu – Catedra de Farmacologie UMF “Carol Davila” Bucureşti
** Dr. Liviu Stoleru – asistent Catedra de Fiziologie – UMF “Carol Davila” Bucureşti
Abstract
Valsartan (Diovan) is a new AT, angiotensin II receptor blocker which appropriately controls blood presure levels in hypertensive patients. Its efficacy, good safety as well as the low incidence of secondary effects, reccommends Nalsartan as first line treatment in hypertension.